These are all good results (aligned with what was expected from the median results) but expecting a moon shot, here is premature. Remember, in sept 21 - we announced three new HER Vaxx trials. It is ongoing.
From the proactive... article today... "Imugene also welcomes news that the Cohort Review Committee (CRC) involved in the trial has approved a new higher dose of HER-Vaxx (100µg) for use in for two upcoming gastic cancer trials due to kick off soon – the nextHERIZON (pretreated metastatic HER2 positive gastric cancer) and neoHERIZON (perioperative HER2 positive gastric cancer) studies."
Imagine what it will be like with a. higher dose... and b. perioperative patients. Sorry but I think the big gains are about 12-18 months away. Buyout/licensing then. Welcome to biotech - more waiting.
Of course who knows where Checkvacc will be by then.
Ann: Final HER-Vaxx Phase 2 Trial Overall Survival Results, page-124
-
- There are more pages in this discussion • 316 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.002(3.51%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.7¢ | 5.9¢ | 5.5¢ | $1.012M | 18.02M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 590122 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 1408449 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |